Effect of Preoperative Pupil Size on Quality of Vision After Wavefront-Guided LASIK
NCT ID: NCT00889941
Last Updated: 2009-04-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
51 participants
INTERVENTIONAL
2004-05-31
2005-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Methods: Fifty-one patients underwent LASIK for low myopia and completed questionnaires regarding specific visual symptoms before and after surgery. Each eye was evaluated postoperatively at 1-week, 1-, 3-, 6- and 12-months. Pupils were stratified according to size: small (\<5.5mm), medium (5.5 to 6.0mm) and large (\>6.0mm). Mesopic pupil size and preoperative and postoperative variables were evaluated using analysis of variance (ANOVA). A regression model was also performed to determine the correlation between mean spherical equivalent and cylinder and visual symptoms.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
small
LASIK
laser-assisted in situ keratomileusis
medium
LASIK
laser-assisted in situ keratomileusis
large
LASIK
laser-assisted in situ keratomileusis
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
LASIK
laser-assisted in situ keratomileusis
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. no more than 3.00 D of refractive astigmatism
3. a stable refraction (less than 0.50D per year of sphere or cylinder)
4. a corneal diameter of less than 11.0 mm to allow for suction ring fixation
5. discontinuation of soft contact wear at least 7 days prior to preoperative evaluation
6. visual acuity correctable to at least 20/20
7. age older than 21 years
8. ability to participate in follow-up examinations for 12 months after LASIK surgery
Exclusion Criteria
2. severe dry eye symptoms
3. severe blepharitis
4. anterior segment abnormalities (i.e. cataracts, corneal scarring, or neovascularization within 1 mm of intended ablation zone)
5. recurrent corneal erosion
6. severe basement membrane disease
7. progressive or unstable myopia or keratoconus
8. unstable corneal mires on central keratometry
9. corneal thickness in which LASIK procedure would result in less than 250 microns of remaining posterior corneal thickness below the flap postoperatively
10. baseline standard manifest refraction of more than 0.75 D in sphere power
11. or a difference of greater than 0.50 D in cylinder power compared with baseline standard cycloplegic refraction
12. a baseline standard cycloplegic refraction differing more than 0.75 in sphere, 0.50 D in cylinder
13. have a different type of astigmatism (i.e. with-the-rule) when the cylinder is greater than 0.50D compared to baseline standard cycloplegic refraction
14. preoperative assessment of ocular topography and/or aberrations indicates that either eye is not suitable candidate for LASIK vision correction procedure (i.e. forme fruste keratoconus
15. corneal warpage, or pellucid marginal degeneration)
16. previous intraocular or corneal surgery
17. history of herpes zoster or simplex keratitis
18. patients on systemic corticosteroid or immunosuppressive therapy
19. immunocompromised subjects or clinically significant atopic disease
20. connective tissue disease
21. diabetes
22. steroid responder
23. macular pathology
24. pregnant or lactating patients
25. patients with sensitivity to planned study concomitant medications
26. patients participating in another ophthalmic drug or device clinical trial
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Stanford University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Stanford University
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Annie Chan
Role: SUB_INVESTIGATOR
Stanford University
Edward E. Manche
Role: PRINCIPAL_INVESTIGATOR
Stanford University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Stanford University School of Medicine
Stanford, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SU-02082009-1758
Identifier Type: -
Identifier Source: org_study_id